SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Big fish eats small, takeover of the company. Art collage.
Deals
Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business
With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.
October 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Abstract two arrows go around on a dark blue background. Digital exchange and money transfer concept. Low poly wireframe vector illustration in futuristic hologram style. Polygonal recycle symbol.
Gene editing
Reusing data could cut R&D costs and greatly increase gene editing’s reach: ARM
Leveraging recently proposed regulatory flexibilities, the gene-editing sector is working to cut R&D costs and unlock indications that were previously economically unviable, according to a new playbook published by the Alliance for Regenerative Medicine.
October 8, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Blue holographic globe with nodes connected around earth. Concept of global network connection, communication technology, fintech, data exchange, worldwide exchange of information and online banking.
Manufacturing
Merck barred from making subcutaneous Keytruda in 8 European countries
With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.
October 8, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Ohio state flag waving in the wind with the national US flag on a clear day. 3D illustration render. Rippled textile. Selective focus
Manufacturing
Bayer commits $2.2B to build pharma manufacturing plant in Ohio
The investment will equip Bayer to make oncology, cardiovascular and renal care ingredients and drugs.
October 7, 2026
 · 
2 min read
 · 
Nick Paul Taylor
3d illustration of automated hand holding medical drugs on blue background with space for text and images.
Manufacturing
Compliance concerns hinder rollout of AI in drug manufacturing: Survey
While AI is taking off in biopharma for administrative tasks and drug discovery efforts, more than 90% of drugmakers have yet to commit to scaling AI use in regulated biopharma manufacturing, according to CRB’s new Horizons: Life Sciences report.
October 6, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Planet Earth. The radiance of the cities of Asia, India and China. 3D rendering. Day to night cycle High resolution texture maps included (normal map / bump map / specular map / color map) Animation created in Blender. https://commons.wikimedia.org/wiki/File:Ocean-wind-atmosphere-ice-arctic-terrain-1123814-pxhere.jpg
Manufacturing
Varda raises $251M to leverage gravity in space for drug production
Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules.
October 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Illustration of a yellow envelope on a blue background with a read warning symbol
Manufacturing
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
Patients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.
October 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A closed sign hanging on the door of a business
Manufacturing
BioNTech to close German manufacturing plants after failing to find buyers
Time has run out on BioNTech’s bid to locate buyers for sites in Idar-Oberstein, Marburg and Tübingen. Including staff at a Singapore plant also slated for closure, the move could impact 1,860 jobs.
September 30, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business or economic growth concept with arrow icons on wooden cubes on blue background
Manufacturing
3 steps for taking on Novartis in radiopharma: Curium up first
To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
September 29, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Vector illustration
Manufacturing
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”
September 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Weight loss pills available: A heap of GLP-1 pills
Manufacturing
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.
September 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor
China flag on bar chart concept with increasing values, economic recovery and business improving after crisis and other catastrophe as economy and businesses reopen again
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
Deals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.
September 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Email envelope with warning sign on white background
Manufacturing
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
After reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to implementing significant design remediations.
September 16, 2026
 · 
2 min read
 · 
Nick Paul Taylor
financial bad statistics. Stagflation, economic slow down. Consumer Price Index. cart with money falls down. bad statistics loss of money. financial crisis or bankruptcy. Money loss. Money inflation
Drug pricing
AAM sounds alarm on ‘unsustainable, race to the bottom’ for generics and biosimilars
After years of price pressures, the trade group argues “the economics of generics have deteriorated to the point where sustainability of the industry is in peril.”
September 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Creative poster collage of two business partners having deal financial payment giving money banknote isolated on beige color background.
Manufacturing
Samsung Biologics inks $262M manufacturing deal with European pharma company
The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.
September 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor